FDA panel narrowly favors CV efficacy claim for Jardiance

On Tuesday, FDA's Endocrinology and Metabolic Drug Advisory Committee voted 12-11 that data from the EMPA-REG OUTCOME cardiovascular outcomes

Read the full 194 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE